We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why ISRG Is Lowering Instrument Costs Despite Strong Profitability
Read MoreHide Full Article
Key Takeaways
ISRG plans to extend EndoWrist instrument life in 2027 to lower costs for select robotic procedures.
ISRG's I&A revenues rose 18% to $1.73B in Q2, but longer instrument use could pressure revenue per procedure.
ISRG's 42% adjusted operating margin supports its strategy to expand adoption through lower costs.
Intuitive Surgical (ISRG - Free Report) is preparing to lower customer costs for selected robotic-assisted procedures through its Extended Use Program (“EUP”), reflecting a strategic trade-off between near-term instrumentation and accessories (I&A) revenues and long-term market expansion.
Beginning first-half 2027, the company plans to increase the useful life of a subset of EndoWrist instruments compatible with its fourth- and fifth-generation da Vinci platforms. The initiative targets benign, high-volume procedures where affordability can influence adoption, particularly in cost-sensitive geographies and healthcare systems with lower reimbursement rates.
The strategy could put pressure on I&A revenue per procedure as customers extend the use of eligible instruments before replacing them. In the second quarter of 2026, I&A revenues rose 18% year over year to $1.73 billion, while da Vinci I&A revenue per procedure reached approximately $1,830, compared with $1,800 a year earlier.
Management is yet to quantify EUP’s financial impact, with further details expected following its analysis and pricing decisions. The rollout is expected to have a gradual impact throughout 2027 rather than result in an immediate, one-time change.
However, Intuitive Surgical is prioritizing growth and profitability together, and believes lower procedure costs can unlock incremental demand. By lowering the cost of robotic surgery for selected benign procedures, EUP could encourage hospitals and physicians to increase utilization, particularly in markets where cost has limited adoption. Higher utilization and a broader customer base could strengthen the company’s installed ecosystem and support recurring revenue opportunities over time.
The initiative comes as Intuitive Surgical remains profitable, reporting a 42% adjusted operating margin in the second quarter. Its broader strategy is to use engineering innovation, manufacturing scale and cost reductions to extend access without compromising product quality or reliability. The near-term trade-off impact will likely lead to slower I&A revenue growth per procedure while driving the longer-term opportunity for a larger market share and higher system utilization.
Peer Updates
Stryker (SYK - Free Report) is improving operating leverage through tighter spending controls, stronger gross margins and operational execution. In the second quarter of 2026, adjusted gross margin increased 60 basis points year over year to 66%, supported by favorable business mix, cost discipline and a net benefit from tariff-related costs.
Adjusted operating margin expanded 170 basis points to 27.4%. Gross margin improvement was complemented by lower adjusted selling, general and administrative expenses as a percentage of sales. Adjusted EPS rose 17.9% to $3.69, outpacing 9% organic sales growth and demonstrating improved profitability despite ongoing recovery from the cybersecurity incident.
Medtronic (MDT - Free Report) is pursuing structural cost reductions through product portfolio simplification, manufacturing efficiencies and supply-chain improvements while continuing to fund growth initiatives. In the first quarter of fiscal 2027, cost-reduction measures contributed 50 basis points to gross margin, net of inflation, while disciplined pricing added another 30 basis points.
The company rationalized more than 9,000 SKUs to streamline operations and improve supply-chain efficiency. Adjusted operating profit increased 15% to $2.3 billion, and operating margin rose 10 basis points to 23.7%, despite unfavorable business mix and higher selling expenses. Management expects operating profit growth of approximately 10% and 50 basis points of margin expansion for fiscal 2027.
View the Zacks #1 Rank List
Image: Shutterstock
Why ISRG Is Lowering Instrument Costs Despite Strong Profitability
Key Takeaways
Intuitive Surgical (ISRG - Free Report) is preparing to lower customer costs for selected robotic-assisted procedures through its Extended Use Program (“EUP”), reflecting a strategic trade-off between near-term instrumentation and accessories (I&A) revenues and long-term market expansion.
Beginning first-half 2027, the company plans to increase the useful life of a subset of EndoWrist instruments compatible with its fourth- and fifth-generation da Vinci platforms. The initiative targets benign, high-volume procedures where affordability can influence adoption, particularly in cost-sensitive geographies and healthcare systems with lower reimbursement rates.
The strategy could put pressure on I&A revenue per procedure as customers extend the use of eligible instruments before replacing them. In the second quarter of 2026, I&A revenues rose 18% year over year to $1.73 billion, while da Vinci I&A revenue per procedure reached approximately $1,830, compared with $1,800 a year earlier.
Management is yet to quantify EUP’s financial impact, with further details expected following its analysis and pricing decisions. The rollout is expected to have a gradual impact throughout 2027 rather than result in an immediate, one-time change.
However, Intuitive Surgical is prioritizing growth and profitability together, and believes lower procedure costs can unlock incremental demand. By lowering the cost of robotic surgery for selected benign procedures, EUP could encourage hospitals and physicians to increase utilization, particularly in markets where cost has limited adoption. Higher utilization and a broader customer base could strengthen the company’s installed ecosystem and support recurring revenue opportunities over time.
The initiative comes as Intuitive Surgical remains profitable, reporting a 42% adjusted operating margin in the second quarter. Its broader strategy is to use engineering innovation, manufacturing scale and cost reductions to extend access without compromising product quality or reliability. The near-term trade-off impact will likely lead to slower I&A revenue growth per procedure while driving the longer-term opportunity for a larger market share and higher system utilization.
Peer Updates
Stryker (SYK - Free Report) is improving operating leverage through tighter spending controls, stronger gross margins and operational execution. In the second quarter of 2026, adjusted gross margin increased 60 basis points year over year to 66%, supported by favorable business mix, cost discipline and a net benefit from tariff-related costs.
Adjusted operating margin expanded 170 basis points to 27.4%. Gross margin improvement was complemented by lower adjusted selling, general and administrative expenses as a percentage of sales. Adjusted EPS rose 17.9% to $3.69, outpacing 9% organic sales growth and demonstrating improved profitability despite ongoing recovery from the cybersecurity incident.
Medtronic (MDT - Free Report) is pursuing structural cost reductions through product portfolio simplification, manufacturing efficiencies and supply-chain improvements while continuing to fund growth initiatives. In the first quarter of fiscal 2027, cost-reduction measures contributed 50 basis points to gross margin, net of inflation, while disciplined pricing added another 30 basis points.
The company rationalized more than 9,000 SKUs to streamline operations and improve supply-chain efficiency. Adjusted operating profit increased 15% to $2.3 billion, and operating margin rose 10 basis points to 23.7%, despite unfavorable business mix and higher selling expenses. Management expects operating profit growth of approximately 10% and 50 basis points of margin expansion for fiscal 2027.